USA (Commonwealth Union)_ Dr. Jay Bhattacharya, a physician and economist trained at Stanford University, has reportedly emerged as the leading candidate to become the next director of the National Institutes of Health (NIH), a prestigious US government agency responsible for biomedical research. Sources familiar with the transition process have indicated that Bhattacharya is a top pick for the role in the incoming administration of President-elect Donald Trump.
Also read: Indian diaspora in Brazil welcomed PM Modi with vedic chants!
The 56-year-old professor, born in Kolkata, India, met recently with Robert F. Kennedy Jr., whom Trump appointed to lead the Department of Health and Human Services (HHS). The HHS is the federal agency overseeing the NIH, as well as other health-related entities. According to media reports, Dr. Bhattacharya impressed Kennedy with his forward-thinking proposals on overhauling the NIH, particularly in regard to shifting the agency’s focus toward supporting more innovative and impactful biomedical research.
Also read: Trump under pressure as Indian Americans push for sanctions!
Bhattacharya’s suggestions also included a call to reduce the influence of longstanding career officials within the NIH, advocating for a more dynamic approach to how the agency operates. The NIH administers substantial research grants, oversees clinical trials, and plays a critical role in the development of new drugs and therapeutics, especially during the ongoing public health challenges posed by the COVID-19 pandemic. However, the decision regarding Bhattacharya’s potential appointment is still not final, as the transition team of President-elect Trump has not made an official announcement.
Also read: 2025 Grammy Awards: Six Indian-origin nominees spark excitement!
Born in Kolkata in 1968, Dr. Jay Bhattacharya has had a distinguished academic career. He earned both his MD and PhD in economics from Stanford University, where he currently serves as a professor of health policy. He also directs the Stanford Center for Demography and Economics of Health and Aging, and is a research associate at the National Bureau of Economic Research. His work predominantly focuses on the health and economic well-being of vulnerable populations, examining the intersection of government health programs, biomedical innovation, and economic policies. Dr. Bhattacharya’s recent research has centered on the epidemiology of COVID-19 and the evaluation of governmental responses to the pandemic. Furthermore, Bhattacharya has made significant contributions to the broader academic fields of health economics, public health, and medical policy. He has authored 135 articles in top-tier scientific journals, covering a wide range of subjects, including the economic implications of population aging, physician performance, and biomedical innovation. Both economics and medical circles highly regard his scholarly work.
In addition to his academic achievements, Dr. Bhattacharya gained public attention as a vocal critic of the US government’s COVID-19 response. In October 2020, he co-wrote the Great Barrington Declaration, which argued against widespread lockdowns and called for more focused protections for vulnerable groups, including older Americans. While the declaration garnered support from some Republican lawmakers and segments of the public eager to resume normal activities, it was met with significant backlash from health experts, including World Health Organization Director-General Tedros Adhanom Ghebreyesus, who called the proposal unethical and unfeasible.
If appointed as NIH director, Dr. Bhattacharya’s approach could bring a fresh perspective to the agency, focusing on innovation and accountability in biomedical research. However, the final decision will ultimately rest with President-elect Trump, whose team continues to consider various options for this influential position. As of now, the appointment of Dr. Bhattacharya to this key health leadership role remains a highly anticipated development in the transition of power in Washington. His extensive expertise in health policy and his bold ideas for reshaping public health research could potentially mark a new direction for the NIH under the Trump administration.
